2019 Healthcare Entrepreneurship & Innovation Exchange
Join us for the 2019 Healthcare Entrepreneurship & Innovation Exchange hosted by the UNC Kenan-Flagler Business School Healthcare Club and the Business of Healthcare Initiative!
This exciting and special spring event will be held at Kenan Center on Monday, April 1st from 5:30 PM to 8:45 PM. We will be hosting founders and executives from local companies to share insight on how start-ups and innovation from within organizations can accelerate the healthcare industry beyond its current boundaries and challenges. Keynote speakers and panelists will discuss industry trends and challenges, how entrepreneurship and innovation can drive progress in the industry, and why students should consider pursuing entrepreneurial initiatives, whether it be starting a new business or adopting an entrepreneurial spirit from within an organization. All UNC students, local alumni, and RTP area professionals are invited!
When: Monday, April 1st, 2019 | 5:30 PM to 8:30 PM
Where: Kenan Center, 300 Kenan Center Drive, Chapel Hill, NC 27599
Organizer Contact: TJ Dolan | TJ_Dolan@kenan-flagler.unc.edu
Check Out Our Schedule of Events
Meet a Few of Our Inspiring Speakers & Experts
Kim Labow, CEO, Medfusion
An accomplished leader with over twenty years of information technology and services experience, Kim has a strong foundation in business strategy, marketing and sales. Her history with Medfusion goes back to its early days, when she worked closely with founder, Steve Malik, serving as the company’s Vice President of Marketing, Product Management and Inside Sales. Following senior executive positions at leading healthcare technology companies, including NaviNet and ZirMed, Labow rejoined the Medfusion team in 2015 as Vice President of Product Management and Vice President of Marketing and is currently CEO. Outside the office, Kim serves on the board of multiple animal rescue organizations including AniMall Pet Adoption and Outreach Center in Cary, NC and Harvey’s House Rabbit Rescue and Sanctuary in Louisville, KY. She has an MBA in Marketing Management, enjoys travel on her Harley Davidson, and is a devoted Red Sox and Patriots fan.
Scott Quilty, Co-Founder & President, MedScribes
Scott is a Co-Founder and President of MedScribes, where he leads sales, marketing, and client services. He spent the last 5 years as a marketing consultant and director of business development at a leading Washington, DC-based marketing services firm. Prior to that, Scott served 7 years in the U.S. Army, first as a Noncommissioned Officer and later as a Ranger-qualified Infantry Captain with the 10th Mountain Division. He holds a Bachelor’s degree in Political Science from the University of New Hampshire, and an MBA from the University of North Carolina at Chapel Hill. Scott grew up in the shadow of Mt. Monadnock in southern New Hampshire, and now calls Fuquay-Varina, North Carolina home with his wife and two children.
Paul Jaglowski, Co-Founder & CEO Feedtrail
Paul is the Co-Founder and CEO of Feedtrail, the software company that is changing the way healthcare organizations learn from their patients in real time and ensure every patient receives the care he or she deserves.
In addition to founding Feedtrail, Paul is a Board Member of Maison Fortune Oprhanage Foundation, an incredible orphanage and primary school in Hinche, Haiti serving 240 of the future leaders of Haiti.
Investing in Healthcare Startups and Entrepreneurs
Dr. Michael Ackermann, Co-Founder & Chief Business Officer Arrivo Management LLC
Michael is a co-founder and the Chief Business Officer for Arrivo Management LLC. Michael is also the founder of Magnatas, LLC, which supports healthcare companies and venture firms in strategy development, organizational effectiveness and process improvement. His clients have included Elan and Baxter. In addition, he is the co-founder and president of AB Collaborative Investments, an Angel Investment firm, which focuses on local and regional healthcare and IT start-ups.
Previously, Michael served as Senior Vice President for Global Commercial Solutions at Quintiles leading the integration of clinical and commercial activities around pharmaceutical product development, including leading the Medical Communications Division through an organizational, operational and skill upgrade to significantly improve profitability and efficiency. Michael also spent more than 18 years at Eli Lilly and Company where he served as the leader of the US Neuroscience Business Unit where he was responsible for all aspects of the neuroscience business (the largest business unit at Lilly). He grew revenue to over $4B and led the unit’s performance improvement, including the turnaround in Zyprexa sales, while overseeing two successful product launches. During his tenure at Lilly he built and led sales organizations in both primary care and neuroscience. In addition, Michael held leadership positions in market research, global and US pricing and global health outcomes to support Lilly’s strategic initiatives
Michael holds a BS degree in biology from Hampden-Sydney College in Virginia, a PhD in immunology from the Drexel University College of Medicine, and an MBA from the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill. In addition, he served as the Fogarty International Post-doctoral Fellow at the National Institutes of Health/NIEHS where his research focus was in immunotoxicology and tumor immunology. He is a guest lecturer at the Kenan-Flagler School of Business at the University of North Carolina and the Kelly School of Business at Indiana University
Stephen E. Butts, Co-Founder & Chief Executive Officer Arrivo Management LLC
Steve is a co-founder and Chief Executive Officer of Arrivo Management LLC. He has over 20 years of experience in the healthcare industry as an executive as well as various commercial roles including brand leadership, new product planning, business development and sales management. Prior to founding the Company, Steve was the co-founder, President and COO of Aerial BioPharma LLC (“Aerial”), a drug development company that sold its lead drug for narcolepsy to Jazz Pharmaceuticals in 2014. Prior to Aerial, Steve was co-founder and Executive Vice President of Neuronex Inc. (“Neuronex”), a successful drug development company focused on developing treatments for patients with certain seizure disorders. Acorda Therapeutics acquired Neuronex in December 2012. Additionally, he was an original member of the executive team at Addrenex Pharmaceuticals (“Addrenex”), a specialty pharmaceutical development company. Steve served as Vice President of Commercial Operations and played a key role in the company’s sale to Shionogi Pharma in 2009. He has also served as Vice President of Sales & Marketing at BioBehavioral Diagnostics Company, as well as assignments at Eli Lilly and Company and Braintree Laboratories.
Steve is currently the Chairman of the Board of Directors of EnviCor Enterprises LLC, a manufacturing company located in Smithfield, NC, focused on developing products for the restaurant industry. He is also a member of the Board of Directors for Otologic Pharmaceutics, a privately held pharmaceutical company focused on the development of products to treat and prevent hearing loss. Steve serves on two not-for-profit boards. He is a member of the Board of Advisors of the Morehead Planetarium at UNC-Chapel Hill and Board of Directors of the Triangle Futbol Club, a not-for-profit youth soccer club. Steve holds a BS degree in Business Administration and an MBA from the Kenan-Flagler School of Business at UNC-Chapel Hill.
Matt Zuga, Co-Founder & Partner at HighCape Capital
Matt Zuga is co-founder of HighCape Partners, and brings more than 20 years of life sciences investment and banking experience. Mr. Zuga was formerly a Managing Director of Syngenta Ventures, an investment vehicle of Syngenta Corp. He was a founder and managing member of Red Abbey Venture Partners (RAVP), where he is currently a member of the Investment Committee.
His current board memberships include Aziyo Biologics and Alba Therapeutics (Co-Chairman). He has previously served as a Board member for Arginetix, Inc. and Board observer at Advanced BioHealing, Aegerion Pharmaceutical, Sirtris Pharmaceuticals and Stromedix, Inc. Prior to RAVP, Mr. Zuga was Head of Life Sciences investment banking at Legg Mason. Mr. Zuga received an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a B.S. in Business Administration/Finance from The Ohio State University.
Don Rose, Director, Kickstart Venture Services, UNC Office of Technology Commercialization; Founder, Carolina Angel Network
Don Rose is the director of the KickStart Venture Services team within the UNC Office of Technology Commercialization. Don founded Carolina KickStart, a North Carolina Translational and Clinical Sciences program that supports faculty commercialization of biomedical technologies through startup generation. Prior to KickStart, he held senior leadership roles at a number of life science startups. Don was also a general partner with Catalysta Partners (now Hatteras Venture Partners), a seed-stage venture fund specializing in information technology and biotechnology startups. During this time, he was co-founder and CEO of Phase Bioscience, a biomaterials startup spun out of Duke University.
Prior to Catalysta, Don was co-founder and vice president of research and development for Cartesian Technologies, a leader in instrumentation for DNA microarrays and nanoliter dispensing. Prior to Cartesian, he was a research scientist at Glaxo Wellcome (now GSK), where he developed and promoted a number of technologies in bioanalytical chemistry, combinatorial chemistry and high-throughput screening. Prior to Glaxo Wellcome, Don developed various aspects of capillary electrophoreses instrumentation at Hewlett-Packard Laboratories. Don earned his PhD in analytical chemistry and a bachelor’s degree in nutrition from UNC-Chapel Hill. He has published eight papers, two book chapters, a book on commercializing university technologies, and he holds six US patents.
The Future of Biopharma Innovation
John Demaree, Chief Commercial Officer of G1 Therapeutics
Mr. Demaree joined G1 as Chief Commercial Officer in 2018. In this role, he is responsible for all aspects of product commercialization, including marketing, sales, market access and commercial operations. Previously, Mr. Demaree served as Vice President, Oncology Marketing for Astellas where he led several product launches. He has worked for more than 20 years in oncology including roles of increasing leadership at Eli Lilly, Novartis and Abbott.
Mr. Demaree has a strong history of building commercial capabilities and leading multiple successful new product and new indication launches. His areas of expertise include strategy, commercialization, new product launches, market access and reimbursement strategy, internal and external collaboration leadership, and business development and licensing.
Mr. Demaree received his B.S. in Marketing and his MBA in Marketing & Finance from Indiana University.